Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
PLoS One. 2024 Aug 7;19(8):e0307145. doi: 10.1371/journal.pone.0307145. eCollection 2024.
Previous studies about the replicability of clinical research based on the published literature have suggested that highly cited articles are often contradicted or found to have inflated effects. Nevertheless, there are no recent updates of such efforts, and this situation may have changed over time.
We searched the Web of Science database for articles studying medical interventions with more than 2000 citations, published between 2004 and 2018 in high-impact medical journals. We then searched for replications of these studies in PubMed using the PICO (Population, Intervention, Comparator and Outcome) framework. Replication success was evaluated by the presence of a statistically significant effect in the same direction and by overlap of the replication's effect size confidence interval (CIs) with that of the original study. Evidence of effect size inflation and potential predictors of replicability were also analyzed.
A total of 89 eligible studies, of which 24 had valid replications (17 meta-analyses and 7 primary studies) were found. Of these, 21 (88%) had effect sizes with overlapping CIs. Of 15 highly cited studies with a statistically significant difference in the primary outcome, 13 (87%) had a significant effect in the replication as well. When both criteria were considered together, the replicability rate in our sample was of 20 out of 24 (83%). There was no evidence of systematic inflation in these highly cited studies, with a mean effect size ratio of 1.03 [95% CI (0.88, 1.21)] between initial and subsequent effects. Due to the small number of contradicted results, our analysis had low statistical power to detect predictors of replicability.
Although most studies did not have eligible replications, the replicability rate of highly cited clinical studies in our sample was higher than in previous estimates, with little evidence of systematic effect size inflation. This estimate is based on a very select sample of studies and may not be generalizable to clinical research in general.
之前基于已发表文献的临床研究可重复性研究表明,高引用文章经常与后续研究结果相矛盾或发现其效应被夸大。然而,此类研究工作并没有最新进展,这种情况可能随着时间的推移而发生变化。
我们在 Web of Science 数据库中检索了 2004 年至 2018 年期间发表在高影响力医学期刊上的超过 2000 次引用的医学干预研究文章。然后,我们使用 PICO(人群、干预、对照和结局)框架在 PubMed 中搜索这些研究的复制研究。通过复制研究的效应在同一方向上具有统计学意义以及复制的效应大小置信区间(CI)与原始研究的效应大小 CI 重叠来评估复制的成功。还分析了效应大小膨胀的证据和复制的潜在预测因素。
共发现 89 项符合条件的研究,其中有 24 项研究(21 项荟萃分析和 3 项原始研究)有有效的复制研究。其中,21 项(88%)的效应大小 CI 重叠。在 15 项主要结局有统计学差异的高引用研究中,有 13 项(87%)的复制研究也有显著的效应。当同时考虑这两个标准时,我们样本中的复制率为 24 项中的 20 项(83%)。这些高引用研究中没有证据表明存在系统的效应大小膨胀,初始效应和后续效应的平均效应大小比为 1.03[95%CI(0.88,1.21)]。由于反驳结果的数量较少,我们的分析对复制的预测因素的统计能力较低。
尽管大多数研究没有合适的复制研究,但我们样本中高引用的临床研究的复制率高于之前的估计,几乎没有系统的效应大小膨胀的证据。这个估计是基于一个非常有限的研究样本,可能不适用于一般的临床研究。